NetworkNewsBreaks

WednesdayMar 01, 2017 11:50 am

NetworkNewsBreaks – Skyline Medical, Inc. (NASDAQ: SKLN) Shares Skyrocket on Innovative Technology Contract from Vizient, Inc. for STREAMWAY® System

Skyline Medical (NASDAQ: SKLN) shares are up 43% after the company announced it has received an Innovative Technology contract from Vizient, Inc. for its FDA-approved STREAMWAY® System for automated, direct-to-drain medical fluid disposal. Vizient is the largest, member-driven health care performance improvement company in the country with an annual purchasing volume of almost $100 billion. Hospital experts with expertise in this category who serve on one of Vizient’s member-led councils recommended STREAMWAY, which resulted in the contract. Innovative Technology contracts are reserved for technologies that demonstrate an ability to enhance clinical care or patient safety while improving an organization’s care…

Continue Reading

TuesdayFeb 28, 2017 12:25 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on February 28, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: PTLF 25.00% – News: Inks LOI to acquire the assets of Healthy Life Pets TNTY 8.07% – News: Appoints new member to board of directors PAYM 7.11% – News: Subsidiary Basalt America outlines its goal to regulate use of basalt fiber reinforced polymers on American roads TRTC 7.09% – News: Provides update on its dispensary and production facility in San Leandro, California NTFU 6.67% – News: CFN Media Group publishes an article on recent…

Continue Reading

TuesdayFeb 28, 2017 12:25 pm

NetworkNewsBreaks – Neuralstem, Inc. (NASDAQ: CUR) Preclinical Data of NSI-189 Published in Journal of Cellular Physiology

Neuralstem’s (NASDAQ: CUR) preclinical data on NSI-189 was recently published in the Journal of Cellular Physiology. The study demonstrated that NSI-189 improved behavioral function recovery and enhanced hippocampal synaptic plasticity in stroke-induced animals during the 12-week treatment period, which was maintained up to 24 weeks post-stroke. The study demonstrated that in neurologic and motor deficit tests, the animals treated with NSI-189 performed significantly better than the placebo animals. Additionally, the animals treated with NSI-189 continued to improve during the second 12-week period even in the absence of drug treatment. Histological assessment of stroke-induced brains from NSI-189-treated subjects suggest that NSI-189…

Continue Reading

TuesdayFeb 28, 2017 12:22 pm

NetworkNewsBreaks – NF Energy Saving Corp. (NASDAQ: NFEC) Shares Tick Higher on New Sales Contract

NF Energy (NASDAQ: NFEC) shares are up more than 10% after the energy saving service solutions provider for China's power said it recently signed a $340,000 sales contract with Sinkiang Production and Construction Group to supply a project with butterfly valves. This is the first contract signed in 2017 based upon China's "one belt and one road" developmental strategy for the future. NF Energy intends to use this strategy to expand its market by growing is brand in its local region and nearby countries. Per the agreement, the company is expected to deliver this equipment in the third quarter of…

Continue Reading

TuesdayFeb 28, 2017 9:41 am

NetworkNewsBreaks – aTyr Pharma, Inc.’s (NASDAQ: LIFE) Resolaris™ Granted Orphan Drug Designation for the Treatment of Limb Girdle Muscular Dystrophy; Shares Higher

Shares of aTyr Pharma (NASDAQ: LIFE) are up more than 15% after the company said its lead product candidate, Resolaris™, received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of limb girdle muscular dystrophy (LGMD) patients. Resolaris is derived from a naturally occurring protein released by human skeletal muscle cells and is being developed as an intravenous protein therapeutic for the treatment of rare myopathies with an immune component, such as LGMD. Being granted Orphan Drug Designation by the FDA will advance the development of Resolaris and create opportunity for incentives under the program.…

Continue Reading

TuesdayFeb 28, 2017 9:35 am

NetworkNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Presenting this Morning at the National Investment Banking Association Conference

Market analysis company ChineseInvestors.com, Inc. (OTCQB: CIIX) this morning announced that its management team will be presenting at the National Investment Banking Association Conference, which is currently underway at the Westin New York Grand Central Hotel in Midtown Manhattan. The company will be presenting alongside the WallStreet Research™ team, who is sponsoring ChineseInvestors.com’s participation at the event. Additionally, WallStreet Research™ has organized, for the CIIX management team, a collection of one-on-one meetings with prospective investors for later in the day at the Penn Club in New York. Interested parties can review ChineseInvestors.com’s presentation materials from the conference by visiting the…

Continue Reading

MondayFeb 27, 2017 12:10 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on February 27, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: HTGM 135.77% – News: Announces new direct-target sequencing chemistry available Q1 2017 OWCP 24.37% – News: Receives IRB approval for safety testing on topical cream to treat psoriasis MPAY 20.83% – News: Appoints new member to board of advisors OPCO 14.68% – News: Posts Q4 2016 results ATEA 14.56% – News: Completes independent audit LXRP 12.50% – News: Receives notice of patent to be accepted in Australia AXSM 8.14% – News: CEO presenting corporate…

Continue Reading

MondayFeb 27, 2017 12:07 pm

NetworkNewsBreaks – Cellectar Biosciences, Inc. (NASDAQ: CLRB) Reports Positive Data from Phase I Trial of CLR 131 in Multiple Myeloma; Shares Higher

Cellectar Biosciences (NASDAQ: CLRB) this morning issued a positive update of its phase I clinical study of CLR 131 in patients with relapsed or refractory multiple myeloma. The data show that the 25 mCi/m2 dose was safe and well tolerated, and that adverse events were similar to those in the previous two cohorts. All four cohort 3 patients achieved stable disease and continue to be followed for progression-free survival (PFS) and median overall survival (mOS). While it is premature to report survival-related efficacy data from cohort 3, all patients in cohorts 1 and 2 continue to experience overall survival benefit. …

Continue Reading

MondayFeb 27, 2017 12:04 pm

NetworkNewsBreaks – Pieris Pharmaceuticals (NASDAQ: PIRS) Grants ASKA Pharmaceutical Exclusive Option to License Anemia Drug in Japan

Pieris Pharmaceuticals (NASDAQ: PIRS) this morning announced that it has granted ASKA Pharmaceutical Co., Ltd. an exclusive option to license development and commercial rights to Pieris' anemia drug, PRS-080, in Japan and certain other Asian markets following completion of a multi-dose phase 2a study in dialysis-dependent anemia patients. Per the agreement, Pieris will immediately receive an option payment of $2.75 million. Following an analysis period after the completion of the planned phase 2a study conducted by Pieris, ASKA may exercise its option to obtain an exclusive license to develop and commercialize PRS-080 in Japan, South Korea and certain other Asian…

Continue Reading

MondayFeb 27, 2017 12:01 pm

NetworkNewsBreaks – OncoSec’s (NASDAQ: ONCS) ImmunoPulse® IL-12 Receives Fast Track Designation to Treat Metastatic Melanoma

OncoSec Medical (NASDAQ: ONCS) has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its ImmunoPulse® IL-12, a potentially first-in-class, Intratumoral anti-cancer gene therapy that expresses interleukin-12 (IL-12) for the treatment of metastatic melanoma, following progression on pembrolizumab or nivolumab. The company this morning announced that this designation permits frequent communications and meetings with the FDA, providing opportunity for the upcoming phase 2b PISCES clinical trial of ImmunoPulse® IL-12 in combination with an intravenous anti-PD-1 antibody. The clinical trial is planned to initiate in the first half of 2017. "With the recent presentation of our interim…

Continue Reading